ELI LILLY AND COMPANY Product Liability Accrual, Period Expense
ELI LILLY AND COMPANY (LLY) reported Product Liability Accrual, Period Expense of $0 for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProductLiabilityAccrualPeriodExpense · last filed 2012-02-24
- ELI LILLY AND COMPANY product liability accrual, period expense for fiscal 2010 was $0.00, a 100.00% decline from fiscal 2009.
- ELI LILLY AND COMPANY product liability accrual, period expense for fiscal 2009 was $230.00M, a 84.43% decline from fiscal 2008.
- ELI LILLY AND COMPANY product liability accrual, period expense for fiscal 2008 was $1.48B.
| Period end | Product Liability Accrual, Period Expense 12 month |
|---|---|
| 2010-12-31 | $0.00 10-K · filed 2011-02-22 |
| 2009-12-31 | $230.00M 10-K · filed 2012-02-24 |
| 2008-12-31 | $1.48B 10-K · filed 2011-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |